Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Vext Science's 3-Year RORE % for the quarter that ended in Jun. 2026 was 29.51%.
The industry rank for Vext Science's 3-Year RORE % or its related term are showing as below:
XCNQ:VEXT's 3-Year RORE % is ranked better than 74.71% of 945
companies
in the Drug Manufacturers industry
Industry Median: 3.5
vs XCNQ:VEXT: 29.51
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Vext Science 3-Year RORE % Related Terms
Vext Science 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Vext Science's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Vext Science's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Vext Science (XCNQ:VEXT) has a 3-Year RORE % of 29.51 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Vext Science and its competitors. According to the industry distribution chart, Vext Science ranks #239 out of 945 companies in the Drug Manufacturers industry, placing it in the top 25.3%.
Is Vext Science's 3-Year RORE % too high?
Vext Science's current 3-Year RORE % is 29.51. The Drug Manufacturers industry median 3-Year RORE % is 3.50. Vext Science's value of 29.51 is 743.1% above this industry median. Based on the distribution chart, Vext Science ranks #239 out of 945 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vext Science has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vext Science's 3-Year RORE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #239 out of 945 companies for 3-Year RORE %. This puts Vext Science in the upper half of its industry. The industry median 3-Year RORE % is 3.50. Vext Science's value of 29.51 is 743.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.50, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current 3-Year RORE % of 29.51 is 743.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current 3-Year RORE % is 29.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Based on GuruFocus' analysis, Vext Science (XCNQ:VEXT) is currently considered Fairly Valued. The stock's GF Value™ is C$0.26, compared to a current price of C$0.26 — trading right at its estimated fair value. The current 3-Year RORE % is 29.51 and 743.1% above the Drug Manufacturers industry median of 3.50. Vext Science's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Vext Science (XCNQ:VEXT), the current 3-Year RORE % is 29.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (XCNQ:VEXT) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of C$0.26 is trading 0% below its estimated GF Value™ of C$0.26.
GuruFocus considers Vext Science to be Fairly Valued.
Key valuation signals for XCNQ:VEXT:
3-Year RORE %: 29.51
GF Value™: C$0.26 vs. price of C$0.26 (0% below fair value)
Industry Position: 743.1% above the Drug Manufacturers median (#239 of 945)
No single metric tells the full story. See the XCNQ:VEXT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc. is a vertically integrated cannabis company operating in the United States. It engages in the cultivation, extraction, manufacturing, distribution, and retail sale of cannabis and cannabis-derived products. The company operates dispensaries under the Herbal Wellness Center brand in Arizona and Ohio, and conducts cultivation and processing in Ohio under the Appalachian Pharm name. Its product portfolio includes brands such as Vapen, Herbal Wellness, Revibe, Prism, and Firebrand, spanning flower, concentrates, vape cartridges, and edibles. Vext Science serves both medical and adult-use cannabis consumers through its own retail locations and wholesale distribution to third-party dispensaries. The company operates as a single reporting segment, with all revenue generated within the United States, primarily from Arizona and Ohio markets. Its business model combines retail dispensary sales with wholesale product distribution.
49GF Score
Get the complete analysis for XCNQ:VEXT
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:VEXT has been successfully added to your 
